Health AI Central
Share:
Peer-Reviewed Publication
Pulm Ther2026August 28, 2026Journal Article

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.

Eileen O Dareng1, Trung N Tran2, Hannah Urbanski3, Ryan Finch4, Ulrika Emerath5, Yulia Kurdyukova5, Maria L Jison6, Lila Bahadori6, Andrew Menzies-Gow7, Eileen Wang8,9, Elisabeth H Bel10, Luis Perez de Llano11, Benjamin Emmanuel2, Lynda Olinger12,13
1Safety Epidemiology and Risk Management, Chief Medical Office, AstraZeneca, City House, 126-130 Hills Road, Cambridge, CB2 1RY, UK. eileen.dareng@astrazeneca.com.
2Respiratory and Immunology, BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA.
3Global Evidence, Global Medical Respiratory, BioPharmaceuticals, AstraZeneca, Cambridge, UK.
4Statistical Programming, Biometrics, BioPharmaceuticals, AstraZeneca, Cambridge, UK.
5Global Patient Safety, BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden.
6Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
7Global Medical Respiratory and Immunology, BioPharmaceuticals, AstraZeneca, Cambridge, UK.
8Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, CO, USA.
9Division of Allergy and Clinical Immunology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
10Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
11Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Spain.
12Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
13Cytel Inc, Waltham, MA, USA.
PubMed DOI

Abstract

INTRODUCTION: Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics, or non-biologic therapies. METHODS: Data from adults with severe asthma accrued to the International Seve…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.